TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05636176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
Study: NCT06333860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Solution for Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Solution for Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Solution for Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Oral tablet
Study: NCT06450353

Intervention type: BEHAVIORAL
Intervention: Patient Ancestry Questionnaires
Description: Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
Study: NCT04891770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: Administered as a sub-cutaneous (SC) injection
Study: NCT06007664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Video to Improve Daily Activity
Description: Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
Study: NCT04895748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor
Study: NCT04891770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: Administered as a sub-cutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously
Study: NCT04891770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Administered as film-coated oral tablets
Study: NCT05840809

Intervention type: DRUG
Intervention: First line tuberculosis treatment
Description: This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
Study: NCT05234437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigilanol tiglate
Description: Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.
Study: NCT04891770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Administered as film-coated oral tablets
Study: NCT04895748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor
Study: NCT05174611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
Study: NCT05655910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition shake
Description: Nutrition shake to support immune health and recovery from surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition shake
Description: Nutrition shake to support immune health and recovery from surgery.
Study: NCT05174611

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
Study: NCT05850351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
Study: NCT05655910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition shake
Description: Nutrition shake to support immune health and recovery from surgery.
Study: NCT05301179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein quantity and quality
Description: Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein quantity and quality
Description: Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
Study: NCT05252390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-868
Description: NUV-868 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-868
Description: NUV-868 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-868
Description: NUV-868 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-868
Description: NUV-868 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-868
Description: NUV-868 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-868
Description: NUV-868 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib
Study: NCT04895748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: Adenosine A2A antagonist receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: Adenosine A2A antagonist receptor
Study: NCT05444530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC85135
Description: Participants will receive VAC85135 as IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC85135
Description: Participants will receive VAC85135 as IM injection.
Study: NCT05252390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide
Study: NCT06560229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grocery gift card
Description: Monthly $100 grocery gift cards for 12 months
Study: NCT06565026

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CS-206
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study: NCT06580301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK012
Description: The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
Study: NCT06040970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab
Description: Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab
Description: Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 IV
Study: NCT05444530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab as IV infusion.
Study: NCT05457283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Finerenone in different doses, treatment duration will be 540 ±7 days.
Study: NCT05313529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT04953689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscientiousness Coach
Description: Participants will use the Conscientiousness Coach app to organize their goals and assist them in engaging in more conscientious behaviors. The participant will also be educated about Conscientiousness as it relates to healthy living and accomplishing life goals and values. Participants will receive brief phone calls during weeks 1, 2, 6, and 10 from the research assistant, tracking progress, answering queries, and return visits to the clinic/teleconference will be scheduled for further assistance during week 4 and week 8. These mid-study visits (or 'Booster Sessions') will last approximately 50 minutes and will involve a brief discussion of goal and value progress and app usage; at this in-person meeting/teleconference, similar questions and topics will be covered as in the bi-monthly phone calls. At week 12, there is a treatment termination visit with the principal investigator and research assistant.
Study: NCT06290843

Intervention type: PROCEDURE
Intervention: Schroth method
Description: Exercises from Schoth method

Intervention type: PROCEDURE
Intervention: Schroth method
Description: Exercises from Schoth method
Study: NCT06293508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Health Communication Intervention
Description: Participants in this group will receive links and materials related to breast cancer screening from official sources (e.g. MOH, Non-governmental organizations (NGOs), etc.) that is already readily available and accessible by the Malaysian public. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Change Health Communication Intervention
Description: Participants receive health communication materials designed using persuasive behavioural change communication principles and behavior science to promote breast cancer screening. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
Study: NCT05850351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online
Description: Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
Study: NCT06110754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-STRONG for SCD
Description: I-STRONG for SCD is a group-based, multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training. The intervention includes 16 sessions that occur over 8 weeks. Adolescents attend every session and parents attend 6 of the 16 sessions.
Study: NCT05896150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia AND single-injection paravertebral block
Description: CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection paravertebral block
Description: Paravertebral block with Bupivacaine 0.5%
Study: NCT04639050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
Study: NCT05398263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study: NCT05803798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPL+LLLT
Description: preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
Study: NCT06151704

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: The subject will receive high-intensity laser therapy in a prone position with a cushion under the abdomen and eye protection. The laser scanner, 50 cm from the skin, will target the area from the 12th ribs to the upper iliac crest, 4.2 cm lateral to the spine. The sciatic, tibial, and peroneal nerves will also be irradiated. A GaAlAs laser device will be used, with a power of 1.6 watts and a wavelength of 808nm. The initial dose will be 10 joules/cm², with an increment of 2 joules after every three sessions. The final dose will be 16 joules/cm².

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor control exercise
Description: Motor control exercise is defined as an exercise to increase control and coordination of the spine and pelvis. Normally, Motor control exercise increases the weak deep trunk muscles, such as transversus abdominis and multifidus, and reduces the overactive large external trunk muscles, such as rectus abdominal and erector spinae muscles. . All subjects participate in a foundational treatment regimen involving motor control exercises: isolated and combined contractions of the transverse abdominis and multifidus muscles in various positions. Contractions will initially be performed up to a maximum of 10 repetitions per movement, with each contraction sustained for a duration of 10 seconds. Commencing from the third week, the subject should be capable of comfortably executing 10 repetitions, sustaining the contraction for 10 seconds, and progressively increasing the intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Description: Motor control exercise is defined as an exercise to increase control and coordination of the spine and pelvis. Normally, Motor control exercise increases the weak deep trunk muscles, such as transversus abdominis and multifidus, and reduces the overactive large external trunk muscles, such as rectus abdominal and erector spinae muscles. . All subjects participate in a foundational treatment regimen involving motor control exercises: isolated and combined contractions of the transverse abdominis and multifidus muscles in various positions. Contractions will initially be performed up to a maximum of 10 repetitions per movement, with each contraction sustained for a duration of 10 seconds. Commencing from the third week, the subject should be capable of comfortably executing 10 repetitions, sustaining the contraction for 10 seconds, and progressively increasing the intensity.
Study: NCT05279976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualized Education
Description: The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualized Education
Description: The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
Study: NCT05565378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered
Study: NCT06037200

Intervention type: DEVICE
Intervention: Urin-based test by the DOASENSE Dipstick Device
Description: Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.

Intervention type: DEVICE
Intervention: Urin-based test by the DOASENSE Dipstick Device
Description: Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
Study: NCT05398263

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05099874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndeavorRx
Description: EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
Study: NCT04819971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirelizumab
Description: tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
Study: NCT05565378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelistotug
Description: Nelistotug will be administered.